The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Low-dose weekly decitabine and venetoclax in TP53-mutated myeloid malignancies.
 
Lauren C Shapiro
No Relationships to Disclose
 
Ioannis Mantzaris
No Relationships to Disclose
 
Aditi Shastri
Honoraria - OncLive
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Pharmacy
Research Funding - Kymera
 
Alejandro R. Sica
No Relationships to Disclose
 
Lizamarie Bachier-Rodriguez
No Relationships to Disclose
 
Noah Kornblum
No Relationships to Disclose
 
Kira Gritsman
Research Funding - iOnctura
 
Eric Jay Feldman
Employment - Ichnos Sciences
 
Amit K. Verma
Stock and Other Ownership Interests - Stelexis Therapeutics; ThromboGenics
Consulting or Advisory Role - Acceleron Pharma; Celgene; Novartis
Research Funding - BMS Brazil; Curis; GlaxoSmithKline; Incyte; Lilly; MedPacto
 
Ira Braunschweig
No Relationships to Disclose
 
Yogen Saunthararajah
Stock and Other Ownership Interests - Acceleron Pharma; Celgene; EpiDestiny
Consulting or Advisory Role - EpiDestiny
Patents, Royalties, Other Intellectual Property - -Patents around tetrahydrouridine and decitabine licensed to EpiDestiny. - Unpaid consultancy for EpiDestiny.
 
Mendel Goldfinger
No Relationships to Disclose